CLASS II ONGOING Drug recall · Reported 5 Oct 2022 · FDA Enforcement Report

Rifampin Capsules, USP, 150 mg recalled by Akorn

Akorn is recalling Rifampin Capsules, USP, 150 mg, distributed nationwide in the US. The recall was initiated on 21 Sep 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot#: 3192818, Exp 10/31/2022; 3199700, Exp 03/31/2023; 3203853, Exp 02/29/2024
Quantity recalled18,145 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1547-2022
FDA event ID
90880
Recalling firm
Akorn, Gurnee, IL
Classification
Class II
Status
Ongoing
Recall initiated
21 Sep 2022
FDA classified
28 Sep 2022
Reported
5 Oct 2022
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity

Timeline

21 Sep 2022Recall initiated by company
28 Sep 2022Classified by FDA+7 days
5 Oct 2022Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Rifampin Capsules, USP, 150 mg, 30-count bottle, Rx only, Distributed by: Akorn Operating Company, LLC, Gurnee, IL 60031, NDC 61748-015-30

Where it was distributed

USA Nationwide and Puerto Rico

Nationwide Puerto Rico

Questions about this recall

Is Rifampin Capsules, USP, 150 mg recalled?

Yes. Akorn recalled Rifampin Capsules, USP, 150 mg on 21 Sep 2022. The recall is Class II and its status is Ongoing. Recall number D-1547-2022.

Why was it recalled?

Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).

Which lots are affected?

Lot#: 3192818, Exp 10/31/2022; 3199700, Exp 03/31/2023; 3203853, Exp 02/29/2024

Where was it sold?

USA Nationwide and Puerto Rico

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Akorn

All 192

Other Rifampin recalls

All 20